Abstract

The ultimate objective of the research projects in this application is to improve our understanding of mechanisms of disease in human myeloid leukemias, and to explore new therapeutic options relating to the disease pathways under investigation. It is anticipated that the laboratory and murine will inform the clinical project, and that the clinical insights will feed back to the animal and laboratory projects for further assessment. Members of the Biostatistics core will provide assistance to all the research projects contained in this program.
The specific aims of Core C Biostatistics are: 1. To provide biostatistical collaboration for clinical research protocols. This includes all aspects of the design, conduct, analysis, and reporting of the clinical studies. 2. To provide biostatistical collaboration for the laboratory research studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, as well as the analysis of laboratory results in conjunction with, or as outcomes of, the clinical studies of Project 5. 3. To provide biostatistical collaboration for animal studies, including all aspects of the design and analysis of such studies. 4. To assist in the oversight of data management, other clinical support services, and the tracking of samples to Projects for analysis with data returned and computerized for statistical analysis.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-12
Application #
7882406
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
12
Fiscal Year
2009
Total Cost
$66,730
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Bolin, Sara; Borgenvik, Anna; Persson, Camilla U et al. (2018) Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 37:2850-2862
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117

Showing the most recent 10 out of 376 publications